Abbott Laboratories

Abbott’s management ranks as competent and shareholder-aligned. CEO Robert Ford is an Abbott lifer (joined in 1989) who has steered the company since 2020, earlier serving as Chief Operating Officer and heading devices businesses.

Under his tenure, Abbott navigated the pandemic, redirected resources to high-growth segments (e.g. diabetes care), and managed the 2022 formula recall fallout. The acquisition of St. Jude Medical (2017) remains a success, and R&D spend has been prioritized without reckless M&A bragging.

The leadership has steadily rewarded shareholders with dividends and buybacks without over-leveraging. The board and CEO have strong reputations in healthcare and maintain significant ownership (insiders own ~1–2%).

Risks include the lawsuits over pediatric nutrition; management so far has reserved ~$3B (over 2023–25) to resolve these claims, which seems prudent. Overall we see management as effective professionals (score ~75).

It is not founder-run (Abbott was founded 1900, CEO is not Abbott family), but the team has deep experience in company culture and industry. In quality terms, they are aligned with owners on-critical issues, though not visionary like a tech founder.

Thus we rate management as above average – strong at execution and capital stewardship, facing no obvious red flags.